Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Arthur L ShafferJames D PhelanJames Q WangDaWei HuangGeorge W WrightMonica KasbekarJaewoo ChoiRyan M YoungDaniel E WebsterYandan YangHong ZhaoXin YuWeihong XuSandrine RoullandMichele CeribelliXiaohu ZhangKelli M WilsonLu ChenCrystal McKnightCarleen Klumpp-ThomasCraig J ThomasBjörn HäuplThomas OellerichZachary RaeMichael C KellyInhye E AhnClare SunErika M GaglioneWyndham H WilsonAdrian WiestnerLouis M StaudtPublished in: Blood cancer discovery (2021)
In diffuse large B-cell lymphoma, we show that primary resistance to BTK inhibitors is due to epigenetic rather than genetic changes that circumvent the BTK blockade. We also observed this resistance mechanism in chronic lymphocytic leukemia, suggesting that epigenetic alterations may contribute more to BTK inhibitor resistance than currently thought.See related commentary by Pasqualucci, p. 555. This article is highlighted in the In This Issue feature, p. 549.